uniQure Announces Successful Readministration of Gene Therapy in Non-Human Primates
11 mai 2017 07h00 HE
|
uniQure N.V.
– Effective Transduction Achieved After Readministration of Gene Transfer – – Preclinical Data Presented Today at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in...
uniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates
10 mai 2017 07h00 HE
|
uniQure N.V.
-- Strong Dose-Dependent Transduction in All Animals Tested Regardless of the Level of Anti-AAV5 Antibodies at Pre-Administration -- -- Data Suggests AAV5 Gene Therapies May be Viable...
uniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress
09 mai 2017 07h00 HE
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 09, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company developing transformative therapies for patients with...
uniQure Announces Company Presentations at Upcoming May Conferences
01 mai 2017 07h00 HE
|
uniQure N.V.
-- Investor breakfast event and webcast at ASGCT on Friday, May 12 at 7:00 a.m. EDT -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE),...
uniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at CHDI’s 12th Annual Huntington’s Disease Therapeutics Conference
26 avr. 2017 07h00 HE
|
uniQure N.V.
-- One-time Administration of AMT-130 Demonstrates for the First Time Efficacy in Large Animal Model -- Strong Dose-Dependent Reduction of Mutant Huntingtin Protein and Widespread Vector Distribution...
uniQure Receives European Medicines Agency Priority Medicines (PRIME) Designation for AMT-060 in Hemophilia B
25 avr. 2017 07h05 HE
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 25, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
24 avr. 2017 16h05 HE
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 24, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in Europe
20 avr. 2017 07h00 HE
|
uniQure N.V.
-- Marketing Authorization for Glybera® to Expire on October 25, 2017 ---- Company Maintains Focus on Core Programs in Hemophilia B, Huntington’s Disease and Congestive Heart Failure --LEXINGTON,...
uniQure Publishes Data Demonstrating Wide Distribution of AAV5 in the Central Nervous System
04 avr. 2017 07h42 HE
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 04, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Presentations at Upcoming April Conferences
03 avr. 2017 07h00 HE
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 03, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...